Merck HQ Germany  photo: Bloomberg Merck unveils €20m Israel electronics incubator

The PMatX Yavne incubator will serve Israeli startups and focus on next-generation electronics and advanced materials.

Teva Photo: Reuters Teva, Histadrut reach partial agreement on layoffs

The number of layoffs at Neot Hovav has been reduced from 175 to 110 but there is still no agreement at the Kfar Saba plant.

Teva Photo: Tamar Matsafi $2b bids expected for Teva's women's health assets - report

US companies Church & Dwight Co. and Cooper Cos. are both interested in Teva's women's health portfolio, "Bloomberg" reports.

Copaxone US Congress to investigate Copaxone price hikes

Teva has raised the price of Copaxone 10-fold since 1996, two US Congressmen claim.

Teva  photo: Reuters Teva launches generic testosterone boost treatment

Teva has announced the launch of generic Axiron (testosterone) topical solution. Axiron has annual sales of $247 million in the US.

Dr. Ehud Marom Drug development co Mapi Pharma raises $10m

The financing is for a Phase III trial for the Israeli company’s lead product, Glatiramer Acetate (Copaxone) Depot, for treating multiple sclerosis.

Yaron Neudorfer  Photo: Ilya Melnikov Social Finance Israel raises NIS 20m for diabetes treatment

The National Insurance Institute pays investors if the treatment is successful.

Medicine Photo: Reuters Prescription error elimination co MedAware raises $8m

The Israeli company has developed algorithm-rich solutions for the detection and elimination of prescription errors.

drugs, medicine  picture: thinkstock Robot drug dispensing co RescueDose raises $2.5m

The investing company is ERA Brazil Israel, owned by Eric Ben-Mayor and partners.

Teva Photo: Tamar Matsafi Cerberus, Advent eye Teva assets - report

Foreign media reports say the investment funds are interested in buying Teva's oncology and pain treatment divisions.

Mori Arkin Sol-Gel planning Nasdaq IPO at $200-300m valuation

The dermatology company's unique wrapping method makes it possible to combine two anti-acne drugs.

Mori Arkin Photo: Jonathan Bloom Arkin slams Teva for not foreseeing generics crisis

Biotech and medical devices investor Mori Arkin: The global generics market is in a terrible state, but it wasn't unexpected.

Exalenz Exalenz Bioscience plans Nasdaq IPO

Controlling shareholder Mori Arkin told "Globes" that he hopes the Israeli diagnostics company's IPO will be at a company value of $200-300 million.

Avi Tiomkin  photo: Einat Levron Teva's collapse could happen to Israeli economy

Israel is putting too many eggs in the startup basket, warns Avi Tiomkin.

Dr. Oron Yacoby-Zeevi Photo: PR How we achieved Israel's biggest-ever pharma exit

CSO Dr. Oron Yacoby-Zeevi tells about the day Neuroderm almost closed down, and how Israeli venture capital funds missed the opportunity to invest.

Teva  photo: PR Nobody would buy Teva because of its debt

Pharmaceutical rivals will to try to exploit Teva's weakness and buy activities from it that are profitable, writes Omri Cohen.

Twitter Facebook Linkedin RSS Newsletters גלובס MAD Conference 2017